2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
26
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
HER2-positive Breast Cancer
3
Advanced Solid Tumor
3
Advanced Breast Cancer
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Cancer With Brain Metastasis
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Interventions
Temozolomide
115
Radiotherapy
63
Magnetic Resonance Spectroscopy
30
Carboplatin
30
Bevacizumab
30
Carmustine
28
Filgrastim
23
Surgical Procedures, Operative
22
Irinotecan
22
Radiation
18
Lomustine
17
Vincristine
15
Etoposide
15
Specimen Handling
13
Peripheral Blood Stem Cell Transplantation
13
O(6)-benzylguanine
13
Radiotherapy, Intensity-Modulated
12
Procarbazine
11
Erlotinib Hydrochloride
11
Cyclophosphamide
11
Chemotherapy, Adjuvant
11
sargramostim
10
Thiotepa
10
Cisplatin
10
Flucytosine
9
Everolimus
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Granulocyte Colony-Stimulating Factor
8
Vorinostat
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Astrocytoma
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled